Literature DB >> 26589415

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Jeannette M Schenk1, Cathee Till2, Ann W Hsing3, Frank Z Stanczyk4, Zhihong Gong5, Marian L Neuhouser6, Juergen K Reichardt7,8, Ashraful M Hoque9, William D Figg10, Phyllis J Goodman11, Catherine M Tangen12, Ian M Thompson13.   

Abstract

BACKGROUND: Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can induce prostate cancer (PCA) in laboratory animals, serum-based epidemiologic studies examining androgens in humans have not consistently supported a role for androgens in prostate carcinogenesis. We examined whether pre-diagnostic serum androgens were associated with PCA risk in the placebo arm of the Prostate Cancer Prevention Trial.
METHODS: In this nested case-control study, cases (n = 1,032) were primarily local-stage, biopsy-detected cancers, and controls (n = 1,025) were biopsy-confirmed to be PCA-free. Pre-diagnostic serum androgens (total testosterone, 3α-androstanediol glucuronide, free testosterone), estrogen-to-testosterone ratio, and sex hormone-binding globulin (SHBG) concentrations were measured in pooled (baseline and year 3) blood samples.
RESULTS: We found no significant associations between serum androgens, estrogen-to-testosterone ratios, or SHBG and risk of total, low (Gleason <7) or high-grade (Gleason 7-10) PCA.
CONCLUSION: Much remains to be learned about the role of androgens in prostate carcinogenesis. Further research is needed to evaluate the role of androgens, timing of exposure, genetic modulators of androgen metabolism, or environmental exposures that may affect androgen influence on prostate carcinogenesis.

Entities:  

Keywords:  Androgens; Prostate Cancer Prevention Trial; Prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26589415      PMCID: PMC4724283          DOI: 10.1007/s10552-015-0695-0

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  28 in total

1.  Sex hormones and the risk of incident prostate cancer.

Authors:  Nicholas A Daniels; Carrie M Nielson; Andrew R Hoffman; Douglas C Bauer
Journal:  Urology       Date:  2010-05-07       Impact factor: 2.649

2.  Circulating steroid hormones and the risk of prostate cancer.

Authors:  Gianluca Severi; Howard A Morris; Robert J MacInnis; Dallas R English; Wayne Tilley; John L Hopper; Peter Boyle; Graham G Giles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

3.  Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.

Authors:  A W Hsing; G W Comstock
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Jan-Feb       Impact factor: 4.254

4.  Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.

Authors:  Alan R Kristal; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Marian L Neuhouser; Frank Z Stanczyk; Lisa W Chu; Sherfaraz K Patel; Ian M Thompson; Juergen K Reichardt; Ashraful Hoque; Elizabeth A Platz; William D Figg; Adrie Van Bokhoven; Scott M Lippman; Ann W Hsing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-09       Impact factor: 4.254

Review 5.  Molecular epidemiology of prostate cancer: hormone-related genetic loci.

Authors:  Anand P Chokkalingam; Frank Z Stanczyk; Juergen K V Reichardt; Ann W Hsing
Journal:  Front Biosci       Date:  2007-05-01

6.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.

Authors:  R K Ross; L Bernstein; R A Lobo; H Shimizu; F Z Stanczyk; M C Pike; B E Henderson
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

7.  Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.

Authors:  Emanuela Taioli; Vestra Sears; Alexis Watson; Rafael E Flores-Obando; Maria D Jackson; Flora A Ukoli; Ilce M de Syllos Cólus; Pedro Fernandez; Norma McFarlane-Anderson; Elaine A Ostrander; Iara S Rodrigues; Janet L Stanford; Jack A Taylor; Marshall Tulloch-Reid; Camille C R Ragin
Journal:  Prostate       Date:  2012-11-05       Impact factor: 4.104

8.  Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.

Authors:  Jiri Heracek; Richard Hampl; Hampl Richard; Martin Hill; Hill Martin; Luboslav Starka; Starka Luboslav; Jana Sachova; Sachova Jana; Jitka Kuncova; Kuncova Jitka; Vaclav Eis; Eis Vaclav; Michael Urban; Urban Michael; Vaclav Mandys; Mandys Vaclav
Journal:  Steroids       Date:  2007-02-13       Impact factor: 2.668

9.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

Authors:  Andrew W Roddam; Naomi E Allen; Paul Appleby; Timothy J Key
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

10.  Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer.

Authors:  Boris Gershman; Irene M Shui; Meir Stampfer; Elizabeth A Platz; Peter H Gann; Howard L Sesso; Natalie DuPre; Edward Giovannucci; Lorelei A Mucci
Journal:  Eur Urol       Date:  2013-01-11       Impact factor: 20.096

View more
  11 in total

1.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Robin J Leach; Teresa L Johnson-Pais; Ann W Hsing; Ashraful Hoque; Howard L Parnes; Jeannette M Schenk; Catherine M Tangen; Ian M Thompson; Juergen K V Reichardt; William D Figg
Journal:  Cancer       Date:  2016-05-10       Impact factor: 6.860

2.  Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.

Authors:  Kai Wang; Xinguang Chen; Victoria Y Bird; Travis A Gerke; Todd M Manini; Mattia Prosperi
Journal:  Int J Cancer       Date:  2017-07-24       Impact factor: 7.396

3.  The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Susan Chadid; John R Barber; William G Nelson; Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Frank Z Stanczyk; Howard L Parnes; Scott M Lippman; Angelo M De Marzo; Elizabeth A Platz
Journal:  Prostate       Date:  2020-06-07       Impact factor: 4.104

4.  Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Li Tang; Mary E Platek; Song Yao; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Yue Wu; Elizabeth A Platz; Marian L Neuhouser; Frank Z Stanczyk; Juergen K V Reichardt; Regina M Santella; Ann Hsing; William D Figg; Scott M Lippman; Ian M Thompson; Christine B Ambrosone
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

5.  Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations.

Authors:  Michael B Cook; Frank Z Stanczyk; Shannon N Wood; Ruth M Pfeiffer; Muhannad Hafi; Carmela C Veneroso; Barlow Lynch; Roni T Falk; Cindy Ke Zhou; Shelley Niwa; Eric Emanuel; Yu-Tang Gao; George P Hemstreet; Ladan Zolfghari; Peter R Carroll; Michael J Manyak; Isabell A Sesterhann; Paul H Levine; Ann W Hsing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-08-22       Impact factor: 4.254

6.  Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy.

Authors:  Dordaneh Sugano; Abhinav Sidana; Amit L Jain; Brian Calio; Sonia Gaur; Mahir Maruf; Maria Merino; Peter Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  Int Urol Nephrol       Date:  2019-12-05       Impact factor: 2.370

7.  Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Cindy H Chau; Cathee Till; Douglas K Price; Phyllis J Goodman; Marian L Neuhouser; Michael N Pollak; Ian M Thompson; William D Figg
Journal:  Endocr Relat Cancer       Date:  2022-01-20       Impact factor: 5.678

8.  Association of Prudent, Western, and Alternate Healthy Eating Index (AHEI-2010) dietary patterns with serum testosterone and sex hormone binding globulin levels in men.

Authors:  David S Lopez; Lydia Liu; Stephanie A Smith-Warner; Konstantinos K Tsilidis; Carrie Daniel; Jacques Baillargeon; Sabine Rohrmann; Elizabeth A Platz; Edward Giovannucci
Journal:  Hormones (Athens)       Date:  2022-01-11       Impact factor: 3.419

9.  Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.

Authors:  Cindy Ke Zhou; Frank Z Stanczyk; Muhannad Hafi; Carmela C Veneroso; Barlow Lynch; Roni T Falk; Shelley Niwa; Eric Emanuel; Yu-Tang Gao; George P Hemstreet; Ladan Zolfghari; Peter R Carroll; Michael J Manyak; Isabell A Sesterhenn; Paul H Levine; Ann W Hsing; Michael B Cook
Journal:  Prostate       Date:  2017-10-02       Impact factor: 4.104

10.  Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men.

Authors:  Eleanor L Watts; Paul N Appleby; Demetrius Albanes; Amanda Black; June M Chan; Chu Chen; Piera M Cirillo; Barbara A Cohn; Michael B Cook; Jenny L Donovan; Luigi Ferrucci; Cedric F Garland; Graham G Giles; Phyllis J Goodman; Laurel A Habel; Christopher A Haiman; Jeff M P Holly; Robert N Hoover; Rudolf Kaaks; Paul Knekt; Laurence N Kolonel; Tatsuhiko Kubo; Loïc Le Marchand; Tapio Luostarinen; Robert J MacInnis; Hanna O Mäenpää; Satu Männistö; E Jeffrey Metter; Roger L Milne; Abraham M Y Nomura; Steven E Oliver; J Kellogg Parsons; Petra H Peeters; Elizabeth A Platz; Elio Riboli; Fulvio Ricceri; Sabina Rinaldi; Harri Rissanen; Norie Sawada; Catherine A Schaefer; Jeannette M Schenk; Frank Z Stanczyk; Meir Stampfer; Pär Stattin; Ulf-Håkan Stenman; Anne Tjønneland; Antonia Trichopoulou; Ian M Thompson; Shoichiro Tsugane; Lars Vatten; Alice S Whittemore; Regina G Ziegler; Naomi E Allen; Timothy J Key; Ruth C Travis
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.